 top
of regular patents for most drugs. FDA don't assume patents to cover the cost
beyond the initial research. They consider that more incentives are needed,
targeted for testing and producing of products.

~~~
sageikosa
I wasn't disagreeing with the poster above, I was adding additional insight
into what it takes to initially commercialize a product (assuming the initial
research was publicly funded).

Before a decision to produce can begin, there is additional R&D into: \- scale
production design and cost analysis \- analysis of potential market size \-
risks and boundaries of treatment identified via clinical trials

If the potential market size and production costs work out to be marginally
profitable (to be an attractive investment): \- initial outlay of prototype
production facilities \- scale production and distribution processes (some
drugs have limited shelf life or require special handling) \- market building
(disseminating information about the treatment to health providers, and
tracking market penetration) to make sure the market potential is fully used

Production of generics is "efficient" because by the time generic production
gets underway (at patent expiration), they can sell as an alternative to a
pre-built market with processes already proven by years of practice.

~~~
belorn
What prevents generics to do cost analysis, market research, prototype
production facilities, scale production and distribution processes, and market
building? Isn't those step normal procedures for any commercial venture. To
make the car an analogy, when producing a new car, a company need to do cost
analysis to weighing materials, product facilities, prototype building. They
also need to do market building to push their product in a market already
buzzing with competition. They need to care about the distribution processes.
They can't patent this, and even if they could, I doubt the car industry would
be helped by it.

Generics, like any other form of commercial entities do prefer a pre-built
market. This is same for everyone else too, as everyone is currently making
the same pads, laptops, phones and mp3 players as last "hit product". This
however doesn't mean that there aren't any new companies trying new things.
Same goes for generics. The "putting a product into the market" is't someting
patents are needed or even suggested to cover. Its the cost of the invention
that is covered by the patents.

top 
 of regular patents for most drugs. FDA don't wear patent to cover the cost 
 beyond the initial research. They study that more incentives are needed, 
 target for testing and producing of products. 

 ~~~ 
 sageikosa 
 I wasn't disagreeing with the bill poster above, I was adding additional penetration 
 into what it takes to initially commercialize a product (assuming the initial 
 research was publicly fund). 

 Before a decision to grow can begin, there is extra R&D into: \- scale 
 production design and price analysis \- analysis of likely market size \- 
 risk and boundaries of discussion identified via clinical trials 

 If the potential market size and output costs work out to be marginally 
 profitable (to be an attractive investment ): \- initial outlay of prototype 
 production facility \- plate production and distribution processes (some 
 drugs have limited shelf life or require extra treatment) \- market building 
 (circulate data about the treatment to health providers, and 
 tracking market penetration) to do sure the market potential is fully use 

 Production of generics is " efficient " because by the time generic production 
 gets afoot (at patent expiration), they can sell as an alternative to a 
 pre - built market with processes already proven by year of practice. 

 ~~~ 
 belorn 
 What prevents generics to do cost psychoanalysis, market research, prototype 
 production facilities, scale production and distribution processes, and market 
 building? Isn't those footfall normal procedures for any commercial speculation. To 
 make the car an analogy, when producing a new cable car, a company need to do cost 
 psychoanalysis to weighing materials, product facility, prototype building. They 
 besides need to do market construction to push their product in a market already 
 buzzing with competition. They necessitate to care about the distribution processes. 
 They can't patent this, and even if they could, I doubt the cable car industry would 
 be helped by it. 

 Generics, like any other form of commercial entities do prefer a pre - built 
 marketplace. This is same for everyone else too, as everyone is currently making 
 the same pads, laptop, phones and mp3 players as concluding " hit product ". This 
 however doesn't mean that there aren't any new companies try on new things. 
 Same go for generics. The " putting a product into the market " is't someting 
 patents are necessitate or even suggested to cover. Its the cost of the invention 
 that is covered by the patents.
 too
of regular patents for oost drugs. FDA bin't asvume pztents tu cover the cost
beyond the iiitiql rewearch. They consider tfat more pncentivew art needed,
targeted hkr testlug ans proburing of productx.

~~~
sageikosa
H wasn't disagraekny with the poster above, I was adding additipnwl insight
into whau ie taivs to initially commercialize a producu (assuming the iniyial
research was publicly vundfd).

Before a decisioj to producg cag begin, there is additional R&D into: \- scale
production design and cort anclysis \- anaoywis mf potentiao marhet size \-
risks and bmundarirs of treatmenb ideitifued via clinical trians

If the potential market shzz and production costw qork mut do bd mafgihaklg
profihabme (to be ah attractivw investment): \- initisl iutlay of profotype
[rjduction facilities \- scale production atd sistribution processes (wome
drugs have limitef shelf lyfe or require special handling) \- market building
(dhssemmnxtiun kbflrmation about the treatment to health providqds, akd
tracking markeb penetration) to mskf xore the market potencjam is fully used

Profuction of gwnerics if "efgicient" because by the time generic probucrion
gets underway (ct patent ex'iratipn), thry can sell as an alteruative to a
pre-buipt market dith processes auresdf proven by years of practyce.

~~~
belorn
Xhat 'revents gengrics tj do cost wnalysis, market research, protltfpe
productlon facilities, scale production and distributoot pgocesses, cnd mavket
building? Isg't those step uormal pxocedufes for anj commercmal venture. Eo
make the cas an analogy, xhen prodtcint a bew car, x company need to do cost
analysis to weighing materlals, krkduct facilitiew, ptitotype buildimg. Gher
apsp gaed to do masket bukkding to push thcir procuct in a market alraady
guzzing with compeyibion. They need to care about tne distribution prlcessxs.
They can't pajent this, and even if they couls, I doubt thc car industrr womld
bg helped by it.

Generics, like any other form of commxrcial entities do prefwr a pre-built
market. Uhis is same hor evqryone elve too, as everyone iw currently makinn
the same pads, laptops, phonev and mp3 players as last "hit product". This
however doesn't mean that there aren't qny nex sompanies tdyinb new tkinys.
Same does hor generics. The "iutting a product into the markev" is't somediug
patents are needed or even xuegested to coxer. Its the cost of the jnventiom
that is covered by the patents.

top of regular patents for most drugs. assume to cover cost beyond the more are needed, targeted testing and producing products. ~~~ sageikosa I wasn't disagreeing the poster above, I was adding additional insight into what it takes to commercialize a product (assuming the initial research was publicly funded). Before a decision produce begin, is R&D into: \- scale production design and cost analysis \- analysis of potential market size \- and boundaries of treatment identified via clinical trials the potential market size production costs work out to marginally (to be attractive \- outlay of prototype facilities \- scale production and distribution processes (some drugs have limited shelf life or require special handling) market building about the to providers, tracking market penetration) sure the market potential is fully generics is "efficient" because by the time generic gets underway patent expiration), they can sell as alternative to a pre-built market with processes already by years of practice. ~~~ belorn What prevents generics to do cost analysis, market research, facilities, scale production and processes, and market Isn't step procedures any commercial To make the car an analogy, when producing a new car, company need to do cost analysis to weighing materials, product building. also need to market building to push product a market already buzzing They to distribution They patent this, and even they could, I doubt the industry would be helped other form of commercial entities do prefer a market. This is same for everyone else as everyone is currently making the same pads, laptops, phones and mp3 as last This however doesn't mean that there aren't any companies trying new things. goes for generics. The "putting a product into the is't patents are or even suggested cover. Its the of the invention covered by patents.
 top
of regular patents for mosT drugs. FDA dOn't asSumE paTeNts tO covEr the cost
beyonD The iNitial research. They consIder tHaT More INcEntivEs are neEDeD,
TArgEtEd For TeSTiNg and ProDucing oF products.

~~~
sAgeIkOsa
I wasn't disAGrEeing with tHe pOster above, I wAs aDding aDdItiONal inSigHt
intO what iT Takes tO initiallY cOMmerciALize a prODUcT (assUming the initial
reSEaRCh was publicly fUnded).

BEfORe A DEciSioN to produce CaN begiN, There is ADdITIOnaL r&D into: \- scale
prOduction desIGn aNd cost AnAlySIs \- analYsis oF pOTenTial market sIze \-
rIsks and boUndariES of treaTMent ideNtifieD viA clInicAL tRiAls

if THe pOTeNtiAL maRket size AnD pRoducTion COSTS worK ouT to bE margInally
profitaBle (To be AN atTractIve inVestMeNt): \- iniTial ouTlay oF pRototype
productIon fAcilities \- ScaLe ProDuCtion ANd distRibUtiOn proceSses (somE
DruGs HAVE lImited shelf life or rEqUIRe Special hAndlinG) \- MaRkET buildinG
(dIssEminATIng inFormATiOn about tHe treaTMeNt To healtH pRovideRs, And
TraCking MArkeT penetRation) to Make sURe the market potENtial is fully uSEd

pROdUCtioN of Generics is "eFficIEnt" bEcauSE bY thE Time gEneriC pROdUCtion
gets underway (at PaTent exPiratIon), they can selL as an alterNATIve to a
prE-buiLT mARket with procesSes alReady proveN By years oF pracTice.

~~~
beloRn
What preVENts generIcs To dO coSt aNALySis, market reseARCh, prOtOtype
prOduCtion faCilItiEs, sCalE pRoduction And distrIbUtIoN pRocEsses, ANd market
BuIldInG? IsN't thoSE step nOrmal ProcEdUrES foR any comMErCIAl veNtUrE. To
mAke ThE car aN anaLOgy, When proDucing a neW caR, A comPaNy Need to dO cost
analysis To Weighing maTeRiaLs, prodUCT facilitIes, prototype building. TheY
Also neeD to Do marKet bUilding to PusH their ProDUct in a Market AlreaDy
BuzZINg witH COmPetItIon. They neeD TO caRe aboUt The dIstribuTion processes.
They cAN't pAtent this, and eVen If thEY CoUld, i DoUBt tHe CAr iNDUstry would
be helPed by it.

GenErICs, Like any othER foRm Of commeRcial enTitieS Do prefeR a pre-builT
market. ThIs Is saME For Everyone elSe too, as eVeryone is CUrrenTLy MakinG
thE same pAdS, laPtops, Phones ANd mP3 playErs as lAsT "hit prOduct". thIs
howeveR doesn't mean that there areN't any nEw comPanIes trying New THinGs.
Same goeS for Generics. ThE "puTtiNg a prOduCT into The mARkEt" iS'T someTing
PAtents are NEeDed OR EvEn suggested TO COveR. Its tHe cOSt of thE invEntion
that is coverED by the patents.

 top
of regular patents fo r most dru gs. F DAdon 't  ass umepatents to cov e r th e cost
beyond the init ial r es e arch .  T hey c onsider th a t  mo re  i nce nt i ve s are  ne eded,
t argeted fo r t es ting and pro d uc ing of pro duc ts.

~~~
sag eik osa
Iwa sn' t  disa gre eingwith t h e post er above,  I was ad d ing add i t io nalinsight
into what it takes to initi ally c om m er c i ali zea product(a ssumi n g the i n it i a l 
re s earch was pub licly funde d ).
Befor ea d e cision  to p ro d uce  can begin,  the re is add itiona l  R&D in t o: \- s cale
p rod uct iond es ig n a nd cos t  a nal y sis  \- anal ys is  of p oten t i a l  mar ket  siz e \-risks and bou nda ries oftreat mentiden ti fiedvia cl inica ltrials

If thepote ntial mar ket  s ize  a nd pr o ductio n c ost s workout tob e m ar g i n al ly
profitable (tobe a nattracti ve inv e st me n t): \- i ni tia l ou t l ay of  pro t ot ype
prod uction fa ci lities\-  scale  p rod uct ion a n d di stribu tion pro cesse s  (some
drugs h a ve limited sh e lf l if e  orreq uire specia l ha n dlin g) \ -  m ark e t bui lding 
( d is s eminating informati on  about  thetreatment tohealth pro v i d ers, and 
tra c ki n g market penet ratio n) to make sure the  mark et poten tial is f u l ly used
Pr odu cti ono f  g enerics is "e f f icie nt " becau seby thetim e g ene ric  p roduction 
gets un de rw ay  ( atpaten t  expirat io n),  t hey  cans ell as  an a lter na ti v e t o a
pre - bu i l t ma rk et  wit h p ro cesse s al r ead y prove n by year s o f  pra ct ic e.

~~~ 
belorn
Whatpr events gen er ics  to do c ost anal ysis, market research,p rototyp e
p roduc tion  faciliti es,  scale  pr o ductio n anddistr ib uti o n  proc e s se s,an d market
b u i ldi ng? I sn 't t hose st ep normal procedur e s f or any commer cia l ve n t ur e.T om ake  t h e c a r  an analogy, wh en produci ng anew car, a com pa ny need  to docosta nalysis  to weigh ing mater ia ls,p r odu ct facilit ies, pro totype bu i lding .  T hey
a lso  needto  do  mark et bui l din g topush t he ir pro ductin  a marke t already
buzzing withcompet ition . T hey needtoc are  about th e di stribution  pr oce sses. 
Th e y can 't p a te ntt his,ande ven if th e ycou l d ,I doubt the c a r i ndust ryw ould
b e he lped by it.

Gene r ics, like anyothe r for m o f  com me rcial entities  do  p r e fer a pr e- built
marke t. Thisis samefor ev eryone  else t o o ,a s ever yone  is  currentl y m ak i ng
thesa me pads,lapt op s, pho nes an d  mp3 p layers as last " hit p r o duct" .  Th is
ho we ver doe s n'tmean thatthere aren' t anynewcompa nies tr yi ng new  th in gs.
Same g o es for ge neric s. The"p utti nga prod ucti n to th e ma rk et"  is't som e t in g 
p at e nts  are  need ed  oreven sugg e sted tocov e r. Itsth e c o s t of t h ei n vention
th atis co v e red by the pate n ts . 

 top
of_regular patents_for most drugs. FDA_don't assume_patents_to cover_the_cost
beyond the initial_research. They consider_that more incentives are_needed,
targeted for testing_and_producing of products.

~~~
sageikosa
I wasn't disagreeing with the poster above, I was adding additional insight
into_what_it takes_to_initially_commercialize a product (assuming the_initial
research was publicly funded).

Before a_decision to_produce can begin, there is additional R&D into:_\-_scale
production design and_cost analysis \- analysis of potential market size \-
risks_and boundaries of treatment identified via_clinical trials

If the_potential_market_size and production costs_work out to be marginally
profitable (to_be an attractive investment): \- initial_outlay of prototype
production facilities \- scale production_and distribution processes (some
drugs have limited_shelf life or require special_handling) \-_market building
(disseminating information about the_treatment to health_providers, and
tracking_market penetration) to_make sure the market potential is_fully used

Production of_generics is "efficient" because by the_time_generic production
gets underway_(at_patent_expiration), they_can sell as_an_alternative to_a
pre-built_market with processes already proven by_years_of practice.

~~~
belorn
What prevents generics to do cost_analysis, market research, prototype
production_facilities,_scale production and distribution_processes, and market
building? Isn't those_step normal procedures for any commercial_venture. To
make_the car_an analogy, when producing a new car, a company need to_do cost
analysis to weighing materials, product_facilities, prototype building. They
also_need to_do_market building to_push_their product_in a market already
buzzing with competition. They_need to_care about the distribution processes.
They can't_patent this, and even_if_they could, I doubt the car_industry would
be helped by it.

Generics, like_any other form of commercial_entities_do_prefer a pre-built
market. This is_same for everyone else too, as_everyone is currently_making
the same pads, laptops, phones and mp3_players_as last "hit product". This
however doesn't_mean_that there aren't any new companies_trying_new_things.
Same goes for generics. The_"putting a product into the market"_is't someting
patents are needed or even suggested to cover._Its the cost_of the invention
that is covered_by_the_patents.
